Latest News

Uncategorized

ESMO 2019: Erdatitinib versus Available Therapies in Advanced Urothelial Cancer: A Matching Adjusted Indirect Comparison

Barcelona, Spain (UroToday.com) Erdafitinib is a pan-FGFR inhibitor which recently garnered accelerated US FDA approval for patients with locally advanced or metastatic platinum-refractory urothelial cancer harboring fusions in FGFR2 or FGFR3 or activating mutations in FGFR3. This approval was based upon the results of BLC2001, a single-arm phase II study of 99 patients in which […]

Uncategorized

ESMO 2019: Hyperphosphatemia Due to Erdafitinib and Anti-tumor Activity Among Patients with Advanced Urothelial Cancer

Barcelona, Spain (UroToday.com) Genomic alterations in FGFR are known to occur in approximately 20% of advanced urothelial cancers,1 with activating mutations in FGFR3 and fusions involving FGFR2 and FGFR3 thought to both drive oncogenesis and render tumors susceptible to FGFR inhibition. Erdafitinib is a pan-FGFR inhibitor which recently received accelerated approval by the US FDA […]

Uncategorized

ESMO 2019: Multiple-cohort Analysis Investigating FGFR3 Alteration as a Predictor of Non-response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer – A Medical Oncologist’s Perspective

Barcelona, Spain (UroToday.com) Neoadjuvant platinum-based chemotherapy is the standard of care for muscle-invasive resectable urothelial carcinoma. As many patients are not eligible for chemotherapy or refuse it, the PURE-01 (NCT02736266) study1 examined the efficacy of neoadjuvant pembrolizumab (anti-PD1) immunotherapy on response rates. The authors showed an encouraging 42% pCR after three treatments of pembrolizumab in patients […]

Uncategorized

ESMO 2019: The Associated of CD8 Infiltration and PD-L1 Expression and Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab, NIVOREN GETUG-AFU 26 Translational Study

Barcelona, Spain (UroToday.com) NIVOREN GETUG AFU 26 is a French multicenter, prospective, phase 2 study that reported safety and efficacy of nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) in a “real world setting.” Results, presented at the GU ASCO 2019 meeting, were notable for a response rate of 21% with a median progression-free survival […]

Uncategorized

ESMO 2019: NIVOREN GETUG-AFU 26 Translational Study: CD8 Infiltration and PD-L1 Expression are Associated with Outcome in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab

Barcelona, Spain (UroToday.com) NIVOREN GETUG AFU 26 is a French multicenter, prospective, phase 2 study that reported safety and efficacy of nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) in a “real world setting.” Results, presented at the GU ASCO 2019 meeting, were notable for a response rate of 21% with a median progression-free survival […]

Uncategorized

ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses

Barcelona, Spain (UroToday.com) Surgical resection is the treatment of choice for Stage 1-3 renal cell carcinoma. As of 2016, SEER data suggests that 16% of patients are diagnosed with the locoregional disease at the time of presentation, and up to 40% of these patients recur with metastatic disease. Multiple studies have looked at the role […]

Uncategorized

ESMO 2019: Primary Renal Tumour Shrinkage in Patients who did not Undergo Upfront Cytoreductive Nephrectomy: Subgroup Analysis from Phase 3 JAVELIN Renal 101 Trial

Barcelona, Spain (UroToday.com) On the basis of noninferiority outcomes for patients with metastatic disease who received sunitinib versus patients who underwent upfront cytoreductive nephrectomy followed by sunitinib,1 the role of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (RCC) who require systemic therapy has been revised. However, the activity of new combination treatments on […]

Uncategorized

ESMO 2019: Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus Axitinib Alone in Patients with Advanced or mRCC

Barcelona, Spain (UroToday.com) Endoglin is an essential angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of VEGF resistance. TRC105 is an endoglin monoclonal antibody that potentiates the anti-tumor activity of VEGF inhibitors in preclinical models1 and demonstrated a 29% RECIST response rate when combined […]

Uncategorized

ESMO 2019: Health-Related Quality of Life in a Randomized Phase 3 trial of Enzalutamide with Standard First Line Therapy for mHSPC: ENZAMET, an ANZUP-led, International, Co-Operative Group Trial – A Medical Oncologist’s Perspective

Barcelona, Spain (UroToday.com) ENZAmet is an international, cooperative group, randomized phase 3 trial that recently showed, after a median follow-up of 34 months, treatment with enzalutamide, rather than an older non-steroidal antiandrogen, added to standard first-line treatment for metastatic hormone-sensitive prostate cancer (mHSPC), with or without concurrent early docetaxel, resulted in longer progression-free survival (HR 0.40, […]

Uncategorized

ESMO 2019: Efficacy and Biomarker Analysis of Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: Subgroup Analysis from the Phase 3 JAVELIN Renal 101 Trial of First-line Avelumab Plus Axitinib vs Sunitinib

Barcelona, Spain (UroToday.com) Despite advances in clear cell renal cell carcinoma (RCC) treatment, patients with sarcomatoid RCC have a poor prognosis and are more resistant to VEGF-targeted therapy. Sarcomatoid RCC is characterized by immunologic infiltration and compared to other tumors has higher expression of PD-1 and PD-L1 on tumor infiltrating immune cells and tumor cells.1 In […]

X